Kết quả ban đầu điều trị bước hai ung thư phổi không tế bào nhỏ giai đoạn muộn phác đồ docetaxel - ramucirumab

Abstract

This descriptive study, combining retrospective and prospective designs, was conducted on 64 patients with stage IV or recurrent metastatic non-small cell lung cancer (NSCLC) who received second-line Docetaxel–Ramucirumab, aiming to evaluate treatment efficacy and adverse effects in real-world clinical practice. Collected variables included age, gender, smoking status, histopathology, performance status, targeted therapy, first-line regimen and response, time interval between first-line and second-line therapy, and docetaxel dosage. The objective response rate (ORR) was 29.7%, the disease control rate (DCR) was 73.4%, and the median progression-free survival (PFS) was 4.9 months (95% CI: 3.3 – 6.5). Multivariable logistic regression showed that age ≥ 65 years old was independently associated with a lower risk of disease progression compared with age < 65 years old (aOR = 0.19; p = 0.047), while poor first-line treatment response independently increased the risk of disease progression (aOR = 4.48; p = 0.030). Common toxicities included fatigue (46.9%), neutropenia (21.9%), and elevated liver enzymes (35.9%); hypertension and hemorrhage occurred at low frequencies and were predominantly mild in severity. The Docetaxel–Ramucirumab regimen demonstrates favorable efficacy and manageable toxicity as second-line treatment for stage IV or recurrent metastatic NSCLC.